S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

Blueprint Medicines (BPMC) Stock Forecast, Price & News

+0.41 (+0.72%)
(As of 05/20/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
431,821 shs
Average Volume
633,497 shs
Market Capitalization
$3.42 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive BPMC News and Ratings via Email

Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter.

Blueprint Medicines logo

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$180.08 million
Book Value
$14.80 per share


Net Income
$-644.09 million
Net Margins
Pretax Margin




Free Float
Market Cap
$3.42 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.62 out of 5 stars

Medical Sector

82nd out of 1,416 stocks

Pharmaceutical Preparations Industry

30th out of 677 stocks

Analyst Opinion: 4.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

Blueprint Medicines (NASDAQ:BPMC) Frequently Asked Questions

Is Blueprint Medicines a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 4 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Blueprint Medicines stock.
View analyst ratings for Blueprint Medicines
or view top-rated stocks.

When is Blueprint Medicines' next earnings date?

Blueprint Medicines is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Blueprint Medicines

How were Blueprint Medicines' earnings last quarter?

Blueprint Medicines Co. (NASDAQ:BPMC) released its quarterly earnings results on Tuesday, May, 3rd. The biotechnology company reported ($1.79) earnings per share for the quarter, beating the consensus estimate of ($1.80) by $0.01. The biotechnology company had revenue of $62.70 million for the quarter, compared to analysts' expectations of $39.98 million. Blueprint Medicines had a negative trailing twelve-month return on equity of 35.24% and a negative net margin of 293.97%. The firm's revenue for the quarter was up 190.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.72) EPS.
View Blueprint Medicines' earnings history

What guidance has Blueprint Medicines issued on next quarter's earnings?

Blueprint Medicines updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $180.00 million-$200.00 million, compared to the consensus revenue estimate of $192.34 million.

What price target have analysts set for BPMC?

10 brokerages have issued 12-month price targets for Blueprint Medicines' shares. Their forecasts range from $65.00 to $152.00. On average, they expect Blueprint Medicines' share price to reach $103.73 in the next twelve months. This suggests a possible upside of 80.8% from the stock's current price.
View analysts' price targets for Blueprint Medicines
or view top-rated stocks among Wall Street analysts.

Who are Blueprint Medicines' key executives?
Blueprint Medicines' management team includes the following people:
  • Mr. Jeffrey W. Albers J.D., M.B.A., MBA, Exec. Chairman (Age 51, Pay $1.2M) (LinkedIn Profile)
  • Ms. Kathryn Haviland, Pres, CEO & Director (Age 46, Pay $733.96k)
  • Mr. Alexis A. Borisy A.M., Co-Founder & Director (Age 50, Pay $45k)
  • Mr. Michael Landsittel, CFO & Treasurer (Age 50, Pay $585.5k)
  • Dr. Fouad Namouni M.D., Pres of R&D (Age 53, Pay $661.58k) (LinkedIn Profile)
  • Ms. Tracey L. McCain Esq., Exec. VP, Chief Legal Officer, Chief Compliance officer & Sec. (Age 54, Pay $716.83k) (LinkedIn Profile)
  • Ms. Christina Rossi, Chief Operating Officer (Age 46)
  • Ms. Ariel Hurley, Principal Accounting Officer, VP of Fin. & Controller (Age 48) (LinkedIn Profile)
  • Dr. Christopher K. Murray, Sr. VP of Technical Operations (Age 59)
  • Dr. Percy H. Carter M.B.A., Ph.D., Chief Scientific Officer (Age 51)
What is Jeff Albers' approval rating as Blueprint Medicines' CEO?

5 employees have rated Blueprint Medicines CEO Jeff Albers on Glassdoor.com. Jeff Albers has an approval rating of 100% among Blueprint Medicines' employees. This puts Jeff Albers in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Blueprint Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), QUALCOMM (QCOM), Amarin (AMRN), CRISPR Therapeutics (CRSP) and Nektar Therapeutics (NKTR).

When did Blueprint Medicines IPO?

(BPMC) raised $115 million in an initial public offering on Thursday, April 30th 2015. The company issued 7,200,000 shares at $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Blueprint Medicines' stock symbol?

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

Who are Blueprint Medicines' major shareholders?

Blueprint Medicines' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.27%), BlackRock Inc. (9.04%), Wellington Management Group LLP (6.56%), State Street Corp (3.81%), Cadian Capital Management LP (3.23%) and JPMorgan Chase & Co. (2.81%). Company insiders that own Blueprint Medicines stock include Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, Christina Rossi, Debra Durso-Bumpus, Fouad Namouni, George Demetri, Jeffrey W Albers, Kate Haviland, L Becker Hewes, Mark Alan Goldberg, Nicholas Lydon and Tracey L Mccain.
View institutional ownership trends for Blueprint Medicines

Which major investors are selling Blueprint Medicines stock?

BPMC stock was sold by a variety of institutional investors in the last quarter, including TimesSquare Capital Management LLC, William Blair Investment Management LLC, Bank of New York Mellon Corp, Victory Capital Management Inc., Candriam Luxembourg S.C.A., Eaton Vance Management, American Century Companies Inc., and Northern Trust Corp. Company insiders that have sold Blueprint Medicines company stock in the last year include Ariel Hurley, Fouad Namouni, Jeffrey W Albers, Kate Haviland, L Becker Hewes, and Tracey L Mccain.
View insider buying and selling activity for Blueprint Medicines
or view top insider-selling stocks.

Which major investors are buying Blueprint Medicines stock?

BPMC stock was acquired by a variety of institutional investors in the last quarter, including Cadian Capital Management LP, Farallon Capital Management LLC, State Street Corp, Wellington Management Group LLP, Assenagon Asset Management S.A., Eventide Asset Management LLC, Granahan Investment Management LLC, and Dimensional Fund Advisors LP.
View insider buying and selling activity for Blueprint Medicines
or or view top insider-buying stocks.

How do I buy shares of Blueprint Medicines?

Shares of BPMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Blueprint Medicines' stock price today?

One share of BPMC stock can currently be purchased for approximately $57.37.

How much money does Blueprint Medicines make?

Blueprint Medicines has a market capitalization of $3.42 billion and generates $180.08 million in revenue each year. The biotechnology company earns $-644.09 million in net income (profit) each year or ($11.050010) on an earnings per share basis.

How many employees does Blueprint Medicines have?

Blueprint Medicines employs 495 workers across the globe.

What is Blueprint Medicines' official website?

The official website for Blueprint Medicines is www.blueprintmedicines.com.

How can I contact Blueprint Medicines?

Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at (617) 374-7580 or via email at [email protected].

This page was last updated on 5/22/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.